The NM_000257.4(MYH7):c.5534G>A (p.Arg1845Gln) variant has been identified in 2 individuals with unspecified cardiomyopathy (van Lint FHM 2019 PMID: 30847666; GeneDx pers. comm.), in 1 individual with LVNC (van Waning 2020 PhD Thesis: https://repub.eur.nl/pub/124773/dissertation-van-Waning.pdf) and 1 individual with anthracycline-associated cardiomyopathy (Wasielewski 2014 PMID: 25332820); however, due to the nature of the associated phenotypes, this data is insufficient to apply the PS4 criterion. This variant has also been identified in 0.003% (1/34584) of Latino/Admixed American chromosomes by gnomAD v2.1.1 (PM2; https://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that this variant may impact the protein (PP3). A different pathogenic missense variant has been previously identified at this codon; however, it has been reported to cause myosin storage myopathy and the additional evidence is insufficient to determine the role of this variant in cardiomyopathy conclusively (c.5533C>T p.Arg1845Trp- Variation ID 14114). Therefore, the PM5 criterion has not been applied. In summary, due to insufficient evidence, this variant is classified as uncertain significance for cardiomyopathy in an autosomal dominant manner. MYH7-specific ACMG/AMP criteria applied (Kelly 2018 PMID:29300372): PM2, PP3.